Herpes virus oncolytic therapy reverses tumor immune dysfunction and facilitates tumor antigen presentation

Cancer Biology and Therapy

Volumn 7, Issue 8, 2008, Pages 1194-1205

  Benencia, Fabian ^a,b   Courrèges, Maria C ^a   Fraser, Nigel W ^a   Coukos, George ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Dendritic cells; Herpes; Mouse; Oncolytic; Ovarian tumor; Therapy

Indexed keywords

GAMMA INTERFERON; GLYCOPROTEIN B; GLYCOPROTEIN D; HSV 1716; INTERLEUKIN 12; INTERLEUKIN 4; TUMOR ANTIGEN; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTATION; APOPTOSIS; ARTICLE; CD8+ T LYMPHOCYTE; CELL MATURATION; CELL PROLIFERATION; CHEMOTAXIS; COCULTURE; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DENDRITIC CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; FLOW CYTOMETRY; IMMUNOHISTOCHEMISTRY; LYMPHOCYTE PROLIFERATION; MOUSE; NICK END LABELING; NONHUMAN; OVARY TUMOR; PHAGOCYTOSIS; SPLEEN CELL; TUMOR IMMUNITY; ULTRAVIOLET B RADIATION;

EID: 49749109913     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.7.8.6216     Document Type: Article

References (81)

1. Smith ER and Chiocca EA. Oncolytic viruses as novel anticancer agents: turning one scourge against another. Expert Opin Investig Drugs 2000; 9:311.
2. Alemany R, Balague C and Curiel DT. Replicative adenoviruses for cancer therapy. Nat Biotechnol 2000; 18:723.
3. Heise C and Kirn DH. Replication-selective adenoviruses as oncolytic agents. J Clin Invest 2000; 105:847.
4. Martuza RL. Conditionally replicating herpes vectors for cancer therapy. J Clin Invest 2000; 105:841.
5. Norman KL and Lee PW. Reovirus as a novel oncolytic agent. J Clin Invest 2000; 105:1035.
6. Stojdl DF, Lichty B, Knowles S, Marius R, Atkins H, Sonenberg N and Bell JC. Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat Med 2000; 6:821.
7. Carroll NM, Chiocca EA, Takahashi K and Tanabe KK. Enhancement of gene therapy specificity for diffuse colon carcinoma liver metastases with recombinant herpes simplex virus. Ann Surg 1996; 224:323.
8. Pawlik TM, Nakamura H, Yoon SS, Mullen JT, Chandrasekhar S, Chiocca EA and Tanabe KK. Oncolysis of diffuse hepatocellular carcinoma by intravascular administration of a replication-competent, genetically engineered herpesvirus. Cancer Res 2000; 60:2790.
9. Glorioso JC, DeLuca NA and Fink DJ. Development and application of herpes simplex virus vectors for human gene therapy. Annu Rev Microbiol 1995; 49:675.
10. McKay EM, McVey B, Marsden HS, Brown SM and MacLean AR. The herpes simplex virus type 1 strain 17 open reading frame RL1 encodes a polypeptide of apparent M(r) 37 K equivalent to ICP34.5 of herpes simplex virus type 1 strain F. J Gen Virol 1993; 74:2493.
11. McKie EA, Hope RG, Brown SM and MacLean AR. Characterization of the herpes simplex virus type 1 strain 17+ neurovirulence gene RL1 and its expression in a bacterial system. J Gen Virol 1994; 75:733.
12. Cassady KA, Gross M and Roizman B. The second-site mutation in the herpes simplex virus recombinants lacking the gamma134.5 genes precludes shutoff of protein synthesis by blocking the phosphorylation of eIF-2alpha. J Virol 1998; 72:7005.
13. Chou J, Chen JJ, Gross M and Roizman B. Association of a M(r) 90,000 phosphoprotein with protein kinase PKR in cells exhibiting enhanced phosphorylation of translation initiation factor eIF-2alpha and premature shutoff of protein synthesis after infection with gamma134.5-mutants of herpes simplex virus 1. Proc Natl Acad Sci USA 1995; 92:10516.
14. Andreansky SS, He B, Gillespie GY, Soroceanu L, Markert J, Chou J, Roizman B and Whitley RJ. The application of genetically engineered herpes simplex viruses to the treatment of experimental brain tumors. Proc Natl Acad Sci USA 1996; 93:11313.
15. Brandt CR, Imesch PD, Robinson NL, Syed NA, Untawale S, Darjatmoko SR, Chappell RJ, Heinzelman P and Albert DM. Treatment of spontaneously arising retinoblastoma tumors in transgenic mice with an attenuated herpes simplex virus mutant. Virology 1997; 229:283.
16. Brown SM, Harland J, MacLean AR, Podlech J and Clements JB. Cell type and cell state determine differential in vitro growth of non-neurovirulent ICP34.5-negative herpes simplex virus types 1 and 2. J Gen Virol 1994; 75:2367.
17. Chambers R, Gillespie GY, Soroceanu L, Andreansky S, Chatterjee S, Chou J, Roizman B and Whitley RJ. Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in a scid mouse model of human malignant glioma. Proc Natl Acad Sci USA 1995; 92:1411.
18. Jia WW, McDermott M, Goldie J, Cynader M, Tan J and Tufaro F. Selective destruction of gliomas in immunocompetent rats by thymidine kinase-defective herpes simplex virus type 1. J Natl Cancer Inst 1994; 86:1209.
19. Kesari S, Randazzo BP, Valyi-Nagy T, Huang QS, Brown SM, MacLean AR, Lee VM, Trojanowski JQ and Fraser NW. Therapy of experimental human brain tumors using a neuroattenuated herpes simplex virus mutant. Lab Invest 1995; 73:636.
20. McMenamin MM, Byrnes AP, Pike FG, Charlton HM, Coffin RS, Latchman DS and Wood MJ. Potential and limitations of a gamma34.5 mutant of herpes simplex 1 as a gene therapy vector in the CNS. Gene Ther 1998; 5:594.
21. Mineta T, Rabkin SD and Martuza RL. Treatment of malignant gliomas using ganciclovir-hypersensitive, ribonucleotide reductase-deficient herpes simplex viral mutant. Cancer Res 1994; 54:3963.
22. Mineta T, Rabkin SD, Yazaki T, Hunter WD and Martuza RL. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med 1995; 1:938.
23. Pyles RB, Warnick RE, Chalk CL, Szanti BE and Parysek LM. A novel multiply-mutated HSV-1 strain for the treatment of human brain tumors. Hum Gene Ther 1997; 8:533.
24. Yazaki T, Manz HJ, Rabkin SD and Martuza RL. Treatment of human malignant meningiomas by G207, a replication-competent multimutated herpes simplex virus 1. Cancer Res 1995; 55:4752.
25. Rampling R, Cruickshank G, Papanastassiou V, Nicoll J, Hadley D, Brennan D, Petty R, MacLean A, Harland J, McKie E, Mabbs R and Brown M. Toxicity evaluation of replication-competent herpes simplex virus (ICP34.5 null mutant 1716) in patients with recurrent malignant glioma. Gene Ther 2000; 7:859.
26. Markert JM, Medlock MD, Rabkin SD, Gillespie GY, Todo T, Hunter WD, Palmer CA,Feigenbaum F, Tornatore C, Tufaro F and Martuza RL. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther 2000; 7:867.
27. Coukos G, Makrigiannakis A, Kang EH, Caparelli D, Benjamin I, Kaiser LR, Rubin SC, Albelda SM and Molnar-Kimber KL. Use of carrier cells to deliver a replication-selective herpes simplex virus-1 mutant for the intraperitoneal therapy of epithelial ovarian cancer. Clin Cancer Res 1999; 5:1523.
28. Coukos G, Makrigiannakis A, Kang EH, Rubin SC, Albelda SM and Molnar-Kimber KL. Oncolytic herpes simplex virus-1 lacking ICP34.5 induces p53-independent death and is efficacious against chemotherapy-resistant ovarian cancer. Clin Cancer Res 2000; 6:3342.
29. Blank SV, Rubin SC, Coukos G, Amin KM, Albelda SM and Molnar-Kimber KL. Replication-selective herpes simplex virus type 1 mutant therapy of cervical cancer is enhanced by low-dose radiation. Hum Gene Ther 2002; 13:627.
30. Todryk S, McLean C, Ali S, Entwistle C, Boursnell M, Rees R and Vile R. Disabled infectious single-cycle herpes simplex virus as an oncolytic vector for immunotherapy of colorectal cancer. Hum Gene Ther 1999; 10:2757.
31. Varghese S and Rabkin SD. Oncolytic herpes simplex virus vectors for cancer virotherapy. Cancer Gene Ther 2002; 9:967.
32. Teshigahara O, Goshima F, Takao K, Kohno S, Kimata H, Nakao A and Nishiyama Y. Oncolytic viral therapy for breast cancer with herpes simplex virus type 1 mutant HF 10. J Surg Oncol 2004; 85:42.
33. Thomas DL and Fraser NW. HSV-1 therapy of primary tumors reduces the number of metastases in an immune-competent model of metastatic breast cancer. Mol Ther 2003; 8:543.
34. Miller CG and Fraser NW. Requirement of an integrated immune response for successful neuroattenuated HSV-1 therapy in an intracranial metastatic melanoma model. Mol Ther 2003; 7:741.
35. Miller CG and Fraser NW. Role of the immune response during neuro-attenuated herpes simplex virus-mediated tumor destruction in a murine intracranial melanoma model. Cancer Res 2000; 60:5714.
36. Toda M, Martuza RL, Kojima H and Rabkin SD. In situ cancer vaccination: an IL-12 defective vector/replication-competent herpes simplex virus combination induces local and systemic antitumor activity. J Immunol 1998; 160:4457.
37. Toda M, Rabkin SD, Kojima H and Martuza RL. Herpes simplex virus as an in situ cancer vaccine for the induction of specific anti-tumor immunity. Hum Gene Ther 1999; 10:385.
38. Banchereau J and Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392:245.
39. Mellman I and Steinman RM. Dendritic cells: specialized and regulated antigen processing machines. Cell 2001; 106:255.
40. Bhardwaj N. Processing and presentation of antigens by dendritic cells: implications for vaccines. Trends Mol Med 2001; 7:388.
41. Porgador A, Snyder D and Gilboa E. Induction of antitumor immunity using bone marrow-generated dendritic cells. J Immunol 1996; 156:2918.
42. Steinman RM and Dhodapkar M. Active immunization against cancer with dendritic cells: the near future. Int J Cancer 2001; 94:459.
43. Steinman RM and Pope M. Exploiting dendritic cells to improve vaccine efficacy. J Clin Invest 2002; 109:1519.
44. Fong L and Engleman EG. Dendritic cells in cancer immunotherapy. Annu Rev Immunol 2000; 18:245.
45. Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, Liu YJ, Pulendran B and Palucka K. Immunobiology of dendritic cells. Annu Rev Immunol 2000; 18:767.
46. Salio M, Cella M, Suter M and Lanzavecchia A. Inhibition of dendritic cell maturation by herpes simplex virus. Eur J Immunol 1999; 29:3245.
47. Kruse M, Rosorius O, Kratzer F, Stelz G, Kuhnt C, Schuler G, Hauber J and Steinkasserer A. Mature dendritic cells infected with herpes simplex virus type 1 exhibit inhibited T-cell stimulatory capacity. J Virol 2000; 74:7127.
48. Gabrilovich D, Ishida T, Oyama T, Ran S, Kravtsov V, Nadaf S and Carbone DP. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood 1998; 92:4150.
49. Gabrilovich DI, Chen HL, Girgis KR, Cunningham HT, Meny GM, Nadaf S, Kavanaugh D and Carbone DP. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 1996; 2:1096.
50. Ohm JE, Shurin MR, Esche C, Lotze MT, Carbone DP and Gabrilovich DI. Effect of vascular endothelial growth factor and FLT3 ligand on dendritic cell generation in vivo. J Immunol 1999; 163:3260.
51. Vicari AP, Caux C and Trinchieri G. Tumour escape from immune surveillance through dendritic cell inactivation. Semin Cancer Biol 2002; 12:33.
52. Zhang L, Yang N, Garcia JR, Mohamed A, Benencia F, Rubin SC, Allman D and Coukos G. Generation of a syngeneic mouse model to study the effects of vascular endothelial growth factor in ovarian carcinoma. Am J Pathol 2002; 161:2295.
53. Benencia F, Courreges MC, Conejo-Garcia JR, Mohamed-Hadley A, Zhang L, Buckanovich RJ, Carroll R, Fraser N and Coukos G. HSV oncolytic therapy upregulates interferon-inducible chemokines and recruits immune effector cells in ovarian cancer. Mol Ther 2005; 12(5):789.
54. Lanzavecchia A and Sallusto F. Antigen decoding by T lymphocytes: from synapses to fate determination. Nat Immunol 2001; 2:487.
55. Campadelli-Fiume G, Cocchi F, Menotti L and Lopez M. The novel receptors that mediate the entry of herpes simplex viruses and animal alphaherpesviruses into cells. Rev Med Virol 2000; 10:305.
56. Roizman B. The function of herpes simplex virus genes: a primer for genetic engineering of novel vectors. Proc Natl Acad Sci USA 1996; 93:11307.
57. Seck T, Koch O, Lingen M and Falke D. Influence of glycoproteins B, C and D on the conversion of virus-to-cell attachment from heparin sensitivity to resistance. Acta Virol 1996; 40:179.
58. Scheffer SR, Nave H, Korangy F, Schlote K, Pabst R, Jaffee EM, Manns MP and Greten TF. Apoptotic, but not necrotic, tumor cell vaccines induce a potent immune response in vivo. Int J Cancer 2003; 103:205.
59. Anderson CC and Matzinger P. Danger: the view from the bottom of the cliff. Semin Immunol 2000; 12:231.
60. Berwin B, Hart JP, Pizzo SV and Nicchitta CV. Cutting edge: CD91-independent cross-presentation of GRP94(gp96)-associated peptides. J Immunol 2002; 168:4282.
61. Wells AD and Malkovsky M. Heat shock proteins, tumor immunogenicity and antigen presentation: an integrated view. Immunol Today 2000; 21:129.
62. Baker-LePain JC, Sarzotti M, Fields TA, Li CY and Nicchitta CV. GRP94(gp96) and GRP94 N-terminal geldanamycin binding domain elicit tissue nonrestricted tumor suppression. J Exp Med 2002; 196:1447.
63. Noessner E, Gastpar R, Milani V, Brandl A, Hutzler PJ, Kuppner MC, Roos M, Kremmer E, Asea A, Calderwood SK and Issels RD. Tumor-derived heat shock protein 70 peptide complexes are cross-presented by human dendritic cells. J Immunol 2002; 169:5424.
64. Todryk S, Melcher AA, Hardwick N, Linardakis E, Bateman A, Colombo MP, Stoppacciaro A and Vile RG. Heat shock protein 70 induced during tumor cell killing induces Th1 cytokines and targets immature dendritic cell precursors to enhance antigen uptake. J Immunol 1999; 163:1398.
65. Gabrilovich DI, Corak J, Ciernik IF, Kavanaugh D and Carbone DP. Decreased antigen presentation by dendritic cells in patients with breast cancer. Clin Cancer Res 1997; 3:483.
66. Gabrilovich DI, Ishida T, Nadaf S, Ohm JE and Carbone DP. Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function. Clin Cancer Res 1999; 5:2963.
67. Pollara G, Speidel K, Samady L, Rajpopat M, McGrath Y, Ledermann J, Coffin RS, Katz DR and Chain B. Herpes simplex virus infection of dendritic cells: balance among activation, inhibition and immunity. J Infect Dis 2003; 187:165.
68. Gary-Gouy H, Lebon P and Dalloul AH. Type I interferon production by plasmacytoid dendritic cells and monocytes is triggered by viruses, but the level of production is controlled by distinct cytokines. J Interferon Cytokine Res 2002; 22:653.
69. Coukos G, Makrigiannakis A, Montas S, Kaiser LR, Toyozumi T, Benjamin I, Albelda SM, Rubin SC and Molnar-Kimber KL. Multi-attenuated herpes simplex virus-1 mutant G207 exerts cytotoxicity against epithelial ovarian cancer but not normal mesothelium and is suitable for intraperitoneal oncolytic therapy. Cancer Gene Ther 2000; 7:275.
70. Kutubuddin M, Federoff HJ, Challita-Eid PM, Halterman M, Day B, Atkinson M, Planelles V and Rosenblatt JD. Eradication of pre-established lymphoma using herpes simplex virus amplicon vectors. Blood 1999; 93:643.
71. Wang M, Rancourt C, Navarro JG, Krisky D, Marconi P, Oligino T, Alvarez RD, Siegal GP, Glorioso JC and Curiel DT. High-efficacy thymidine kinase gene transfer to ovarian cancer cell lines mediated by herpes simplex virus type 1 vector. Gynecol Oncol 1998; 71:278.
72. Toda M, Rabkin SD and Martuza RL. Treatment of human breast cancer in a brain metastatic model by G207, a replication-competent multimutated herpes simplex virus 1. Hum Gene Ther 1998; 9:2177.
73. Loercher AE, Nash MA, Kavanagh JJ, Platsoucas CD and Freedman RS. Identificationof an IL-10-producing HLA-DR-negative monocyte subset in the malignant ascites of patients with ovarian carcinoma that inhibits cytokine protein expression and proliferation of autologous T cells. J Immunol 1999; 163:6251.
74. Oyama T, Ran S, Ishida T, Nadaf S, Kerr L, Carbone DP and Gabrilovich DI. Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-kappaB activation in hemopoietic progenitor cells. J Immunol 1998; 160:1224.
75. Nash MA, Ferrandina G, Gordinier M, Loercher A and Freedman RS. The role of cytokines in both the normal and malignant ovary. Endocr Relat Cancer 1999; 6:93.
76. Santin AD, Hermonat PL, Ravaggi A, Cannon MJ, Pecorelli S and Parham GP. Secretion of vascular endothelial growth factor in ovarian cancer. Eur J Gynaecol Oncol 1999; 20:177.
77. MacLean AR, ul-Fareed M, Robertson L, Harland J and Brown SM. Herpes simplex virus type 1 deletion variants 1714 and 1716 pinpoint neurovirulence-related sequences in Glasgow strain 17+ between immediate early gene 1 and the 'a' sequence. J Gen Virol 1991; 72:631.
78. Pan ZK, Ikonomidis G, Lazenby A, Pardoll D and Paterson Y. A recombinant Listeria monocytogenes vaccine expressing a model tumour antigen protects mice against lethal tumour cell challenge and causes regression of established tumours. Nat Med 1995; 1:471.
79. Lutz MB, Kukutsch N, Ogilvie AL, Rossner S, Koch F, Romani N and Schuler G. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J Immunol Methods 1999; 223:77.
80. Schlienger K, Chu CS, Woo EY, Rivers PM, Toll AJ, Hudson B, Maus MV, Riley JL, Choi Y, Coukos G, Kaiser LR, Rubin SC, Levine BL, Carroll RG and June CH. TRANCE- and CD40 ligand-matured dendritic cells reveal MHC class I-restricted T cells specific for autologous tumor in late-stage ovarian cancer patients. Clin Cancer Res 2003; 9:1517.
81. Decker T and Lohmann-Matthes ML. A quick and simple method for the quantitation of lactate dehydrogenase release in measurements of cellular cytotoxicity and tumor necrosis factor (TNF) activity. J Immunol Methods 1988; 115:61.